Figure 5.

Trials to evaluate left ventricular remodelling attenuation post-myocardial infarction. Markedly improved total mortality in patients at risk for heart failure after myocardial infarction in the last 30 years as reflected by declining mortality rates in trials of renin–angiotensin–aldosterone system inhibitors (modified from Pfeffer M, presented at ACC 2021). SAVE, AIRE, and TRACE showed significantly reduced mortality resulting from angiotensin-converting enzyme inhibitors vs. placebo; VALIANT demonstrated equivalence of angiotensin-converting enzyme inhibition and the angiotensin II receptor blocker valsartan; in PARADISE-MI sacubitril/valsartan was not superior to the angiotensin-converting enzyme inhibitor ramipril.